260 results about "Granulocyte" patented technology

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention relates to the technical field of disease curative effect evaluation, and discloses a method for evaluating the curative effect of granulocyte deficiency accompanying fever after hematologic tumor chemotherapy based on machine learning, and the method comprises the steps: S1, collecting and preprocessing multi-center medical data, the data comprising structured clinical data and multi-modal unstructured data; s2, a curative effect prediction model is constructed based on a graph neural network, and a central moment constraint-based graph federal learning training model is adopted, wherein a patient graph is constructed as an original graph and an enhanced graph is generated; respectively processing the original image and the enhanced image through a two-channel image convolutional neural network, and extracting a high-order representation vector; constructing an enhanced perception loss function based on the high-order representation vectors of the original image and the enhanced image; combining a federated learning framework with multi-center data to train a model; and S3, predicting a curative effect evaluation result through the trained curative effect prediction model. The accuracy, the stability and the clinical interpretability of curative effect evaluation are improved.

The antibody disclosed by the invention can specifically target high-virulence klebsiella pneumoniae of different serotypes, and specifically targets klebsiella pneumoniae of K1 and K2 serotypes. The antibody disclosed by the invention can be combined with high-toxicity klebsiella pneumoniae extracellular capsular polysaccharide with high affinity, has very strong neutralizing activity on klebsiella pneumoniae, and can mediate complement and mature neutrophil to neutralize and kill bacteria in an in-vitro killing experiment, so that the bacterial density is reduced, and the killing effect is improved. The traditional Chinese medicine composition can effectively prevent and treat high-toxicity klebsiella pneumoniae clinical infection and effectively improve pulmonary infection, provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance in preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value in development of a new generation of klebsiella pneumoniae medicine.

The invention relates to the technical field of artificial intelligence, in particular to a special child disease classification method based on particle-ball cross-granularity knowledge collaborative feature selection. The method comprises the following steps: firstly, providing a cross-granularity knowledge collaboration method based on granules and balls; further designing a fuzzy rough set model based on particle-ball cross-granularity knowledge collaboration to perform feature selection; according to the method, feature knowledge under different granularity levels is mined and coordinated to realize more robust and more efficient feature selection, so that the accuracy, generalization ability and interpretability of a classification model are improved, and a more reliable technical tool is provided for early screening and auxiliary diagnosis of diseases of special children.

The invention relates to the technical field of general image data processing or generation, in particular to a multi-view indirect immunofluorescence medical image classification interpretation method and system, and the method comprises the steps: mapping an ethanol view, a formaldehyde view and an HEp-2 view to a feature space, and converting into a feature sequence; performing position coding on the feature sequence to obtain position information; based on the feature sequence with the position information, modal identification information is added, and an identification feature sequence is determined; based on the identification feature sequence, executing multi-modal information fusion, and determining a multi-modal feature sequence; based on the multi-modal feature sequence, combining an attention mechanism to determine a long-distance dependency relationship and correlation between the data; and based on the attention mechanism model, outputting the probability of each category to execute classification interpretation. According to the method, the type of the anti-neutrophil cytoplasm antibody fluorescence model can be adaptively and comprehensively judged in combination with the characteristics of fluorescence brightness, forms and the like of different views, and interference existing in a single view is avoided.

The invention discloses lactobacillus paracasei CFCFC018, a microbial agent and application of the lactobacillus paracasei CFCFC018, and belongs to the technical field of microorganisms. The lactobacillus paracasei CFCFC018 is separated from intestinal contents of rural cats in half-farming and half-pastoral areas in Inner Mongolia, does not need genetic engineering modification, can highly express amino acids and neurotransmitters, can remarkably relieve mammary gland alveolar structure damage in mammary gland tissues of rats suffering from mastitis induced by staphylococcus aureus, and has the advantages of being high in safety and good in stability. The thickening of a mammary gland interacellular matrix layer is avoided, the infiltration number of neutrophils is reduced, the damage degree of mammary gland tissues is reduced, and a certain protection effect on the mammary gland tissues is achieved. The research also shows that the strain can reduce the abundance of harmful bacteria in excrement, improve intestinal inflammation and relieve edema of intestinal submucosa, which provides a new thought for preventing and treating mastitis by regulating intestinal microbiota.

Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

To provide methods for managing, treating, or preventing an eosinophil or mast cell related disorder and / or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).SOLUTION: The present invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an antibody which specifically binds to a KIT receptor tyrosine kinase.SELECTED DRAWING: None

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The invention discloses a traditional Chinese medicine prescription for treating myelosuppression after chemotherapy as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine prescription is prepared from ten traditional Chinese medicines including caulis spatholobi, flos caryophylli, astragalus membranaceus, rhizoma cimicifugae, sanguisorba officinalis, hairyvein agrimony, rhodiola rosea, codonopsis pilosula, cinnamon and angelica sinensis, and has the effect of obviously improving myelosuppression after chemotherapy. Meanwhile, the traditional Chinese medicine composition has good curative effects on four types of myelosuppression after chemotherapy, including leucopenia, neutropenia, thrombocytopenia and over-low hemoglobin. The prescription is good in stability, high in safety and remarkable in curative effect.

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

The present application provides antibodies including antigen-binding fragment thereof that specifically recognizing Granulocyte-Macrophage Colony Stimulating Factor Receptor (GM-CSFRα). Also provided are methods of making and using these antibodies.

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I.The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

The present disclosure relates to the use of IgE for identifying individuals with genetic defects that lead to the expression of protein truncations, extended proteins, to a loss of protein expression or to the expression of mutated proteins. The method is based on a skin prick test, wherein IgE that is specific for the protein of interest is administered onto the skin. If the protein or protein variant that is specifically identified by IgE is present in the skin, the IgE, which was allowed to enter the skin by the skin prick, binds the target protein and then the protein-bound IgE triggers mast cells and / or basophiles in the skin to release granules, resulting in the development of a transient allergic reaction.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention discloses a moisturizing and soothing fermentation composition as well as a preparation method and application thereof. The preparation method of the moisturizing and soothing fermentation composition comprises the following steps: (1) inoculating a fermentation substrate containing centella asiatica and paeonia lactiflora with a seed solution of hirsutella asiatica for fermentation so as to obtain a crude fermentation solution; and (2) carrying out heating treatment and filtering treatment on the crude fermentation liquid to obtain the moisturizing and soothing fermentation composition. The moisturizing and soothing fermentation composition prepared by the invention adopts a mode of extracting and preparing multiple components at the same time, a galactose yeast-like bacterium fermentation product filtrate is prepared, and the moisturizing and soothing fermentation composition also contains a centella asiatica extract and a Chinese herbaceous peony extract; the composition can promote the expression of a paphiopedilum A protein gene, reduce the expression of an IL-6 gene and inhibit zebra fish neutrophile granulocyte aggregation; the moisturizing and soothing effects can be shown from multiple angles.

The invention provides a method for detecting eosinophilic granulocyte peroxidase and application thereof, and relates to the technical field of biological detection.The method comprises the steps that a respiratory tract sample and a sample treatment reagent are mixed, dispersion treatment and centrifugation are conducted, supernatant is taken, and a to-be-detected sample is obtained; carrying out magnetic particle chemiluminescence detection on a to-be-detected sample, and judging the content of eosinophilic granulocyte peroxidase according to a luminescence signal value obtained by detection, the final pH value of the reaction system is 8.0-12.0 according to the detection of a light-emitting signal value; the sample treatment reagent is an aqueous solution containing 0.06-0.12% w / v of a reducing agent. The technical prejudice that the EPX detection is interfered by the peroxidase activity of the EPX in the prior art is overcome; and meanwhile, the mucus is uniformly dispersed through dispersion treatment by virtue of a sample treatment reagent containing a reducing agent, so that high-sensitivity and high-specificity full-automatic detection of the respiratory tract sample EPX is realized on the magnetic particle chemiluminescence platform for the first time.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

The invention relates to a biomarker for evaluating progression and prognosis of paraquat poisoning and application of the biomarker. The biomarker is a urine metabolite Inosine. Urine non-target metabonomics analysis shows that the level of the Inosine is low in urine of a patient suffering from early paraquat poisoning, is gradually reduced along with aggravation of the illness state and is remarkably increased in follow-up visit of five years; the prediction efficiency is judged according to the area (AUC) below the working characteristic (ROC) curve of a subject, the Anosine has good efficiency (AUC = 0.806) in judging the progression of paraquat poisoning, has good efficiency (AUC = 0.816) in judging the prognosis aspect in 1-4 days at the early stage of poisoning, and has excellent efficiency (AUC = 0.961) in judging the prognosis aspect in 7-14 days at the progression stage of poisoning. Moreover, the efficiency of the Inosine in predicting the progress and prognosis of paraquat poisoning is better than that of blood routine indexes (such as the number of leukocytes, the percentage of neutrophils and the percentage of lymphocytes) reported in the literature. In conclusion, as the biomarker for prognosis and prognosis of paraquat poisoning, the Inosine shows a good clinical application prospect.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

This invention relates to an efficient particle sphere generation method based on principal component analysis (PCA), belonging to the field of quantum computing. It solves the problem of low data representation efficiency caused by excessive segmentation and noise sensitivity in existing particle sphere algorithms. The technical solution includes: initializing the particle sphere set using a parallel sampling strategy; calculating the splitting gain and setting a threshold; calculating the optimal splitting direction based on the PCA core sample set; splitting the particle spheres along the principal direction and iteratively updating the set. This method achieves efficient data compression, reduces computational complexity, enhances the representation ability of complex geometric structures, and has strong robustness.

The present invention relates to the field of biomedical technologies and provides a method for efficiently capturing neutrophils from peripheral blood for single-cell sequencing by lysing red blood cells. The method includes the following steps: collecting human peripheral blood into an anticoagulant tube containing ethylenediaminetetraacetic acid; taking the ethylenediaminetetraacetic acid anticoagulated whole blood, adding a red blood cell lysate, lysing at room temperature, waiting until the turbid mixed blood solution becomes clear and transparent, waiting for 1 minute, then adding a FACS cell resuspension solution to terminate red blood cell lysis, and centrifuging; adding the FACS cell resuspension solution to slowly resuspend the cells, and centrifuging; adding the FACS cell resuspension solution to slowly resuspend the cells, and centrifuging; adding a phosphate buffer solution to slowly resuspend the cells, and centrifuging. By selecting a suitable anticoagulant, precisely controlling the red blood cell lysis conditions, and performing meticulous cell resuspension and centrifugation operations, the present invention can ensure high neutrophil activity and a low cell debris rate, provide a suitable single-cell suspension for single-cell RNA sequencing, and help analyze the characteristics and functions of various neutrophil subsets.

The application provides a luffa bath liquid with antibacterial and anti-inflammatory functions, which comprises the following components by weight: 10-18 parts of a ketone compound extract as a first component, 22-35 parts of a lignan compound extract as a second component, 2-5 parts of a triterpene compound as a third component, and 20-30 parts of butyl avocadoate as a fourth component. The luffa bath liquid has an effect of inhibiting the respiratory burst of neutrophils to a certain extent, and can prevent the occurrence of allergic diseases and some cardiovascular and cerebrovascular diseases. The effect is obtained by combining the first component, the second component and the third component.

This invention relates to a polynucleotide targeting the PML-RARG fusion gene and its applications. The PML-RARG fusion gene is formed by the fusion of exon 6 of the PML gene and exon 4 of the RARG gene. The polynucleotide contains a first sequence configured to hybridize with genomic DNA near the break junction of the PML-RARG fusion gene, the first sequence being GGAGGCAGCGGTGGAGA. This invention provides a polynucleotide targeting a novel subtype of the PML-RARG fusion gene. Based on this polynucleotide, new acute promyelocytic leukemia (APML) detection compositions and gene editing tools can be developed, providing further support for research on the pathogenesis of this subtype of AML and drug development.